{
    "nctId": "NCT05861635",
    "briefTitle": "The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression",
    "officialTitle": "Union Hospital Affiliated to Huazhong University of Science and Technology",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Neoadjuvant Therapy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Pathological complete remission (pCR) rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18 to 75 years old, male or female;\n2. Early or locally advanced breast cancer confirmed by pathology;\n3. Lymph node positive or lymph node negative, ER and PR negative, T \u2265 2 or lymph node negative, ER positive or PR positive, T \u2265 5;\n4. ECOG PS: 0-1; 5\uff09Patients with low expression of HER-2: HER-2 IHC 1+or HER2 IHC 2+and ISH negative;\n\nExclusion Criteria:\n\n1. Stage IV breast cancer;\n2. Have received anti-tumor treatment or radiotherapy for any malignant tumor in the past five years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or squamous cell carcinoma;\n3. At the same time, other clinical trials have received anti-tumor therapy. If the researcher judges that the patient cannot benefit from the researcher, other anti-tumor therapy can be ended.\n4. The patient has undergone major surgery unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgery;\n5. Previously received ADC drugs, immunosuppressants, anti-HER2 and other treatments.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}